Search results for "peripheral arterial disease."

showing 10 items of 74 documents

Peripheral artery disease, redox signaling, oxidative stress – Basic and clinical aspects

2017

Reactive oxygen and nitrogen species (ROS and RNS, e.g. H2O2, nitric oxide) confer redox regulation of essential cellular signaling pathways such as cell differentiation, proliferation, migration and apoptosis. At higher concentrations, ROS and RNS lead to oxidative stress and oxidative damage of biomolecules (e.g. via formation of peroxynitrite, fenton chemistry). Peripheral artery disease (PAD) is characterized by severe ischemic conditions in the periphery leading to intermittent claudication and critical limb ischemia (end stage). It is well known that redox biology and oxidative stress play an important role in this setting. We here discuss the major pathways of oxidative stress and re…

0301 basic medicineAntioxidantRedox signalingmedicine.medical_treatmentCellular differentiationClinical BiochemistryReview Article030204 cardiovascular system & hematologyPharmacologymedicine.disease_causeBiochemistrychemistry.chemical_compound0302 clinical medicineGene Regulatory Networks610 Medicine & healthlcsh:QH301-705.5chemistry.chemical_classificationlcsh:R5-920Anticholesteremic AgentsReactive Nitrogen Speciesmedicine.symptomlcsh:Medicine (General)Oxidation-ReductionPeroxynitriteSignal Transductionmedicine.medical_specialtyCell signalingAntioxidant therapy610 Medicine & healthNitric oxide03 medical and health sciencesPeripheral Arterial DiseasemedicineHumansExerciseReactive oxygen speciesbusiness.industryOrganic ChemistryClaudication and critical limb ischemiaWalking distanceIntermittent claudicationSurgeryOxidative Stress030104 developmental biologychemistrylcsh:Biology (General)Peripheral artery (occlusive) diseasebusinessReactive Oxygen SpeciesOxidative stressRedox Biology
researchProduct

Pathophysiology of Peripheral Arterial Disease (PAD): A Review on Oxidative Disorders

2020

Peripheral arterial disease (PAD) is an atherosclerotic disease that affects a wide range of the world’s population, reaching up to 200 million individuals worldwide. PAD particularly affects elderly individuals (>65 years old). PAD is often underdiagnosed or underestimated, although specificity in diagnosis is shown by an ankle/brachial approach, and the high cardiovascular event risk that affected the PAD patients. A number of pathophysiologic pathways operate in chronic arterial ischemia of lower limbs, giving the possibility to improve therapeutic strategies and the outcome of patients. This review aims to provide a well detailed description of such fundamental issues as physical exe…

0301 basic medicineCardiovascular eventmedicine.medical_specialtyArterial diseasePopulationPhysical exerciseReview030204 cardiovascular system & hematologyCatalysisInorganic Chemistrylcsh:Chemistry03 medical and health sciences0302 clinical medicineperipheral arterial diseasephysical exerciseInternal medicineHumansMedicineoxidative stressPhysical and Theoretical ChemistryMuscle SkeletaleducationExerciseMolecular Biologylcsh:QH301-705.5Spectroscopypathophysiologyeducation.field_of_studybusiness.industryOrganic ChemistryAtherosclerotic diseaseGeneral Medicineheme oxygenaseArterial Ischemic StrokePathophysiologyComputer Science ApplicationsPeripheralbody regionsperipheral arterial disease; physical exercise; oxidative stress; heme oxygenase; antioxidants; pathophysiologyEarly Diagnosis030104 developmental biologyantioxidantslcsh:Biology (General)lcsh:QD1-999CardiologybusinessBiomarkersHeme Oxygenase-1
researchProduct

Plasma heme oxygenase-1 is decreased in peripheral artery disease patients.

2016

Peripheral artery disease (PAD) is a common manifestation of atherosclerosis. A number of emerging risk factors, including oxidative stress biomarkers, free radicals and heat shock proteins, may add to the established risk factors for cardiovascular disease (CVD). The present study assessed surrogate markers of oxidative stress, including total reduced glutathione (GSH), lipid hydroperoxides (LOOH), isoprostanes, heme oxygenase‑1 (HO‑1) and metabolic biomarkers, such as adiponectin and lactate, in PAD patients (n=27). Healthy age‑matched volunteers (n=27) served as controls. GSH and LOOH were evaluated by measuring total thiol groups and iron oxidation, respectively, by spectrophotometric a…

0301 basic medicineMaleCancer Researchmedicine.medical_specialtyAdipokineOxidative phosphorylationBiologyIsoprostanesmedicine.disease_causeBiochemistry03 medical and health scienceschemistry.chemical_compoundPeripheral Arterial DiseaseInternal medicineGeneticsmedicineHumansAnkle Brachial IndexMolecular BiologyAgedAdiponectinGlutathioneMiddle Agedmedicine.diseaseIsoprostanesGlutathioneHeme oxygenaseOxidative Stress030104 developmental biologyEndocrinologyOncologychemistryImmunologyMolecular MedicineFemaleAdiponectinLipid PeroxidationOxidative stressDyslipidemiaBiomarkersHeme Oxygenase-1Molecular medicine reports
researchProduct

Circulating miR-130a, miR-27b, and miR-210 in Patients With Peripheral Artery Disease and Their Potential Relationship With Oxidative Stress: A Pilot…

2016

Some emerging risk factors such as oxidative stress biomarkers and microRNAs (miRs) may add additional value to the established risk factors for peripheral artery disease (PAD). We enrolled 27 patients with PAD and 27 age-matched controls. We examined the levels of a series of miRs (miR-130a, miR-27b, and miR-210) in serum samples. The level of well-established oxidative stress biomarkers, such as lipid hydroperoxides, isoprostanes, hemeoxygenase-1 (HO-1) and reduced glutathione, was also measured in plasma and their relationship with the miRs was determined. Levels of miR-130a, miR-27b, and miR-210 were significantly increased in patients with PAD when compared to the controls. The level …

0301 basic medicineOncologyMalemedicine.medical_specialtyLipid PeroxidesStatistics as TopicPilot ProjectsDisease030204 cardiovascular system & hematologyIsoprostanesmedicine.disease_cause03 medical and health scienceschemistry.chemical_compoundPeripheral Arterial Disease0302 clinical medicineIsoprostaneRisk FactorsInternal medicinemicroRNAmedicineHumansPilot ProjectIn patientAgedoxidative streHeme OxygenasemicroRNALipid Peroxidebusiness.industryRisk FactorBiomarkerGlutathioneMiddle AgedGlutathioneHeme oxygenaseMicroRNAsOxidative Stress030104 developmental biologychemistryBiomarker (medicine)FemaleCardiology and Cardiovascular MedicinebusinessBody mass indexOxidative stressBiomarkersHeme Oxygenase-1Human
researchProduct

Noncoding RNAs in Critical Limb Ischemia

2020

Peripheral artery disease, caused by chronic arterial occlusion of the lower extremities, affects over 200 million people worldwide. Peripheral artery disease can progress into critical limb ischemia (CLI), its more severe manifestation, which is associated with higher risk of limb amputation and cardiovascular death. Aiming to improve tissue perfusion, therapeutic angiogenesis held promise to improve ischemic limbs using delivery of growth factors but has not successfully translated into benefits for patients. Moreover, accumulating studies suggest that impaired downstream signaling of these growth factors (or angiogenic resistance) may significantly contribute to CLI, particularly under h…

0301 basic medicineRNA UntranslatedAngiogenesisCritical IllnessNeovascularization PhysiologicDisease030204 cardiovascular system & hematologyBioinformaticsArticlePeripheral Arterial Disease03 medical and health sciences0302 clinical medicineIschemiaRisk FactorsmicroRNADiabetes MellitusAnimalsHumansMedicineTherapeutic angiogenesisProgenitor cellHypoxiaInflammationbusiness.industryStem CellsHemodynamicsCritical limb ischemiaHypoxia (medical)Prognosisbody regions030104 developmental biologyGene Expression RegulationRegional Blood FlowArteriogenesismedicine.symptomCardiology and Cardiovascular MedicinebusinessSignal TransductionArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy.

2020

Abstract Background and aims Polyvascular disease (PVD) affects approximately 20% of patients with atherosclerosis and is a strong independent risk factor for ischemic outcomes. However, guidelines do not address screening or treatment for PVD, and there have been no PVD-specific trials. We reviewed subgroup analyses of large randomized controlled trials of more intense antithrombotic therapy to determine whether increased intensity of therapy improved ischemic outcomes in patients with PVD. Methods MEDLINE, MEDLINE in-Process, EMBASE, and the Cochrane Library were queried for randomized controlled trials larger than 5000 patients evaluating secondary prevention therapies in patients with c…

0301 basic medicineRelative risk reductionmedicine.medical_specialtyPopulationCoronary Artery Disease030204 cardiovascular system & hematologyCochrane Librarylaw.invention03 medical and health sciencesPeripheral Arterial Disease0302 clinical medicineRandomized controlled trialFibrinolytic AgentslawRisk FactorsInternal medicineAntithromboticmedicineHumansRisk factoreducationeducation.field_of_studybusiness.industryAbsolute risk reductionAtherosclerosis030104 developmental biologyRelative riskCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsAtherosclerosis
researchProduct

Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER…

2021

Abstract Aims In this secondary analysis of the VOYAGER trial, rivaroxaban 2.5 mg twice/day plus aspirin 100 mg/day was assessed in older adults. Advanced age is associated with elevated bleeding risk and unfavourable net benefit for dual antiplatelet therapy in chronic coronary artery disease. The risk–benefit of low-dose rivaroxaban in patients ≥75 years with peripheral artery disease (PAD) after lower extremity revascularization (LER) has not been described. Methods and results The primary endpoint was a composite of acute limb ischaemia, major amputation, myocardial infarction, ischaemic stroke, or cardiovascular death. The principal safety outcome was thrombolysis in myocardial infarct…

Acute limb ischaemiamedicine.medical_specialtyBrain IschemiaPeripheral Arterial DiseaseRivaroxabanInternal medicineClinical endpointHumansMedicineMyocardial infarctionAgedRivaroxabanAspirinbusiness.industryAbsolute risk reductionNumber needed to harmmedicine.diseaseStrokeCardiologyNumber needed to treatDrug Therapy CombinationCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsTIMIFactor Xa Inhibitorsmedicine.drugEuropean Heart Journal
researchProduct

Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy.

2013

AdultMaleRegistrieRiskMiddle AgedPeripheral Arterial Diseaseatrial fibrillation; cardiovascular disease; peripheral vascular disease; Adult; Aged; Atrial Fibrillation; Female; Humans; Internal Medicine; Italy; Male; Middle Aged; Peripheral Arterial Disease; Prevalence; Registries; Risk; Societies Medical; Ankle Brachial Index; Cardiology and Cardiovascular MedicineItalycardiovascular diseaseperipheral vascular diseaseMedicalAtrial FibrillationInternal MedicinePrevalenceHumansFemaleAnkle Brachial IndexRegistriesSocietiesCardiology and Cardiovascular MedicineSocieties MedicalAgedHuman
researchProduct

Erectile dysfunction is associated with low total serum testosterone levels and impaired flow-mediated vasodilation in intermediate risk men accordin…

2015

Background: The role erectile dysfunction (ED) coupled with low testosterone levels as early markers of atherosclerosis is not well understood. Objectives: To analyze the relationship between serum testosterone levels with both ED and brachial artery flow-mediated vasodilation (FMD), in a primary prevention sample of men. Methods: We enrolled 802 asymptomatic, intermediate CV risk patients, according to the Framingham Risk Score, aged 40e80 years, who underwent the ultrasound examination of FMD, the evaluation of ED and the assessment of total serum testosterone levels. Results: Testosterone levels correlated both with FMD (r ¼ 0.85; p < 0.0001) and IIEF-5 score (rs ¼ 0.65; p < 0.0001…

AdultMalemedicine.medical_specialtyBrachial ArteryFlow mediated vasodilationRisk AssessmentSeverity of Illness IndexAsymptomaticSettore MED/24 - UrologiaPeripheral Arterial DiseaseRisk Factorsmedicine.arteryInternal medicineDiabetes mellitusOdds RatioHumansMedicineTestosteroneErectile dysfunctionBrachial arteryAgedAged 80 and overSerum testosterone levelsChi-Square DistributionFramingham Risk Scorebusiness.industryEndothelial functionTestosterone (patch)Odds ratioMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareVasodilationLogistic ModelsEndocrinologyErectile dysfunctionRegional Blood FlowMultivariate AnalysisLinear ModelsCardiologymedicine.symptomCardiology and Cardiovascular MedicinebusinessBody mass indexBiomarkersAtherosclerosis
researchProduct

One-year results from the DETOUR I trial of the PQ Bypass DETOUR System for percutaneous femoropopliteal bypass

2019

The objective of this study was to evaluate the 1-year safety and effectiveness outcomes associated with the PQ Bypass DETOUR System (PQ Bypass, Milpitas, Calif) for the percutaneous bypass of long-segment femoropopliteal occlusive disease.This prospective, single-arm, multicenter trial enrolled patients with long-segment femoropopliteal arterial disease. The DETOUR System percutaneously deploys modular stent grafts to bypass femoropopliteal lesions through a transvenous route. Eligible patients included those with TransAtlantic Inter-Society Consensus C and D lesions100 mm in length. The primary safety end point was the major adverse event (MAE) rate through 1 month, defined as the composi…

AdultMalemedicine.medical_specialtyPercutaneousAdolescentmedicine.medical_treatmentArterial Occlusive DiseasesKaplan-Meier Estimate030204 cardiovascular system & hematologyAmputation SurgicalLesionPeripheral Arterial DiseaseYoung Adult03 medical and health sciencesPostoperative Complications0302 clinical medicineMulticenter trialOcclusionmedicineHumansPopliteal ArteryProspective Studies030212 general & internal medicineAdverse effectVascular PatencyAgedAged 80 and overbusiness.industryEndovascular ProceduresStentIntermittent ClaudicationMiddle Agedmedicine.diseaseSurgeryFemoral ArteryStenosisTreatment OutcomeFemaleStentsSurgerymedicine.symptomCardiology and Cardiovascular MedicineClaudicationbusinessJournal of Vascular Surgery
researchProduct